Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease
Smith, R. “Let food be thy medicine …”. BMJ 328, 0-g (2004).
Alexis, A. C. Honest nutrition. Can food be medicine? Pros and cons. MedicalNewsToday www.medicalnewstoday.com/articles/can-food-be-medicine-pros-and-cons (2022).
Mente et al. Diet, cardiovascular disease, and mortality in 80 countries. Eur. Heart J. 44, 2560–2579 (2023).
Google Scholar
Sinclair, H. M. Deficiency of essential fatty acids and atherosclerosis, etcetera. Lancet 270, 381–383 (1956).
Google Scholar
Harris, W. S., Calder, P. C., Mozaffarian, D. & Serhan, C. N. Bang and Dyerberg’s omega-3 discovery turns fifty. Nat. Food 2, 303–305 (2021).
Google Scholar
Bang, H. O., Dyerberg, J. & Nielsen, A. B. Plasma lipid and lipoprotein pattern in Greenlandic west-coast Eskimos. Lancet 1, 1143–1145 (1971).
Google Scholar
Bracco, U. & Deckelbaum, R. J. Polyunsaturated Fatty Acids in Human Nutrition (Raven Press, 1992).
Serhan, C. N. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92–101 (2014).
Google Scholar
Metchnikoff, E. Immunity in Infective Diseases (Cambridge University Press, Reprinted 1905); translated by Binnie, F. G.
Metchnikoff, E. Lectures on the Comparative Pathology of Inflammation Delivered at the Pasteur Institute in 1891 Lecture XII (Kegan Paul, Trench, Trübner, 1893); translated from the French by Starling F. A. & Starling E. H. (reprinted by HardPress, 2019).
Libby, P., Tabas, I., Fredman, G. & Fisher, E. A. Inflammation and its resolution as determinants of acute coronary syndromes. Circ. Res. 114, 1867–1879 (2014).
Google Scholar
Ridker, P. M. et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet 401, 1293–1301 (2023).
Google Scholar
Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).
Google Scholar
Bonaventura, A. & Abbate, A. Colchicine for cardiovascular prevention: the dawn of a new era has finally come. Eur. Heart J. 44, 3303–3304 (2023).
Google Scholar
Serhan, C. N. et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21, 325–332 (2007).
Google Scholar
Serhan, C. N. & Chiang, N. Resolvins and cysteinyl-containing pro-resolving mediators activate resolution of infectious inflammation and tissue regeneration. Prostaglandins Other Lipid Mediat. 166, 106718 (2023).
Google Scholar
Serhan, C. N., Libreros, S. & Nshimiyimana, R. E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: preparing SPMs for long COVID-19, human clinical trials, and targeted precision nutrition. Semin. Immunol. 59, 101597 (2022).
Google Scholar
Serhan, C. N. & Levy, B. D. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J. Clin. Invest. 128, 2657–2669 (2018).
Google Scholar
Serhan, C. N. et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192, 1197–1204 (2000).
Google Scholar
Serhan, C. N. et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025–1037 (2002).
Google Scholar
Serhan, C. N. & Petasis, N. A. Resolvins and protectins in inflammation resolution. Chem. Rev. 111, 5922–5943 (2011).
Google Scholar
Serhan, C. N., Dalli, J., Colas, R. A., Winkler, J. W. & Chiang, N. Protectins and maresins: new pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. Biochim. Biophys. Acta 1851, 397–413 (2015).
Google Scholar
Serhan, C. N. et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J. Exp. Med. 206, 15–23 (2009).
Google Scholar
Werz, O. et al. Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity. Nat. Commun. 9, 59 (2018).
Google Scholar
Pouliot, M., Clish, C. B., Petasis, N. A., Van Dyke, T. E. & Serhan, C. N. Lipoxin A4 analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: a role for cyclooxygenase-2 and lipoxins in periodontal disease. Biochemistry 39, 4761–4768 (2000).
Google Scholar
Tabas, I. & Glass, C. K. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339, 166–172 (2013).
Google Scholar
Cotran, R. S. The endothelium and inflammation: new insights. Monogr. Pathol. (23), 18-37 (1982).
Arita, M. et al. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J. Immunol. 178, 3912–3917 (2007).
Google Scholar
Arita, M. et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 201, 713–722 (2005).
Google Scholar
Mancini, J. A., O’Neill, G. P., Bayly, C. & Vickers, P. J. Mutation of serine-516 in human prostaglandin G/H synthase-2 to methionine or aspirin acetylation of this residue stimulates 15-R-HETE synthesis. FEBS Lett. 342, 33–37 (1994).
Google Scholar
Oh, S. F., Pillai, P. S., Recchiuti, A., Yang, R. & Serhan, C. N. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J. Clin. Invest. 121, 569–581 (2011).
Google Scholar
Arita, M. et al. Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions. J. Biol. Chem. 281, 22847–22854 (2006).
Google Scholar
Divanovic, S. et al. Contributions of the three CYP1 monooxygenases to pro-inflammatory and inflammation-resolution lipid mediator pathways. J. Immunol. 191, 3347–3357 (2013).
Google Scholar
Lee, J. Y. et al. Neuronal SphK1 acetylates COX2 and contributes to pathogenesis in a model of Alzheimer’s Disease. Nat. Commun. 9, 1479 (2018).
Google Scholar
Lee, J. Y. et al. N-AS-triggered SPMs are direct regulators of microglia in a model of Alzheimer’s disease. Nat. Commun. 11, 2358 (2020).
Google Scholar
Kim, S. F., Huri, D. A. & Snyder, S. H. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 310, 1966–1970 (2005).
Google Scholar
Dalli, J., Chiang, N. & Serhan, C. N. Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections. Nat. Med. 21, 1071–1075 (2015).
Google Scholar
Bannenberg, G. L. et al. Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 174, 4345–4355 (2005).
Google Scholar
Schwab, J. M., Chiang, N., Arita, M. & Serhan, C. N. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447, 869–874 (2007).
Google Scholar
Malawista, S. E., de Boisfleury Chevance, A., van Damme, J. & Serhan, C. N. Tonic inhibition of chemotaxis in human plasma. Proc. Natl Acad. Sci. Usa. 105, 17949–17954 (2008).
Google Scholar
Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K. & Serhan, C. N. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2, 612–619 (2001).
Google Scholar
Fukunaga, K., Kohli, P., Bonnans, C., Fredenburgh, L. E. & Levy, B. D. Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J. Immunol. 174, 5033–5039 (2005).
Google Scholar
Ji, R. R. Specialized pro-resolving mediators as resolution pharmacology for the control of pain and itch. Annu. Rev. Pharmacol. Toxicol. 63, 273–293 (2023).
Google Scholar
Serhan, C. N. et al. Novel proresolving aspirin-triggered DHA pathway. Chem. Biol. 18, 976–987 (2011).
Google Scholar
Bazan, N. G. Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol. 15, 159–166 (2005).
Google Scholar
Rodriguez, A. R. & Spur, B. W. First total syntheses of the pro-resolving lipid mediators 7(S),13(R),20(S)-resolvin T1 and 7(S),13(R)-resolvin T4. Tetrahedron Lett. 61, 151473 (2020).
Google Scholar
Rodriguez, A. R. & Spur, B. W. First total synthesis of the pro-resolving lipid mediator 7(S),12(R),13(S)-resolvin T2 and its 13(R)-epimer. Tetrahedron Lett. 61, 151857 (2020).
Google Scholar
Chiang, N. et al. Resolvin T-series reduce neutrophil extracellular traps. Blood 139, 1222–1233 (2022).
Google Scholar
Middleton, E. A. et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 136, 1169–1179 (2020).
Google Scholar
Hong, S., Gronert, K., Devchand, P., Moussignac, R.-L. & Serhan, C. N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: autacoids in anti-inflammation. J. Biol. Chem. 278, 14677–14687 (2003).
Google Scholar
Dalli, J., Colas, R. A. & Serhan, C. N. Novel n-3 immunoresolvents: structures and actions. Sci. Rep. 3, 1940 (2013).
Google Scholar
Endo, J. et al. 18-HEPE, an n-3 fatty acid metabolite released by macrophages, prevents pressure overload-induced maladaptive cardiac remodeling. J. Exp. Med. 211, 1673–1687 (2014).
Google Scholar
Kasuga, K. et al. Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J. Immunol. 181, 8677–8687 (2008).
Google Scholar
Schloss, M. J., Swirski, F. K. & Nahrendorf, M. Modifiable cardiovascular risk, hematopoiesis, and innate immunity. Circ. Res. 126, 1242–1259 (2020).
Google Scholar
Croasdell, A. et al. Resolvins attenuate inflammation and promote resolution in cigarette smoke-exposed human macrophages. Am. J. Physiol. Lung Cell Mol. Physiol. 309, L888–L901 (2015).
Google Scholar
Hsiao, H. M. et al. A novel anti-inflammatory and pro-resolving role for resolvin D1 in acute cigarette smoke-induced lung inflammation. PLoS ONE 8, e58258 (2013).
Google Scholar
Thatcher, T. H., Woeller, C. F., McCarthy, C. E. & Sime, P. J. Quenching the fires: pro-resolving mediators, air pollution, and smoking. Pharmacol. Ther. 197, 212–224 (2019).
Google Scholar
Awji, E. G. et al. Wood smoke enhances cigarette smoke-induced inflammation by inducing the aryl hydrocarbon receptor repressor in airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 52, 377–386 (2015).
Google Scholar
Dominguez, E. C. et al. Aspirin-triggered resolvin D1 reduces chronic dust-induced lung pathology without altering susceptibility to dust-enhanced carcinogenesis. Cancers 14, 1900 (2022).
Google Scholar
Ramar, M., Yano, N. & Fedulov, A. V. Intra-airway treatment with synthetic lipoxin A4 and resolvin E2 mitigates neonatal asthma triggered by maternal exposure to environmental particles. Int. J. Mol. Sci. 24, 6145 (2023).
Google Scholar
Bevan, G. H., Al-Kindi, S. G., Brook, R. D., Munzel, T. & Rajagopalan, S. Ambient air pollution and atherosclerosis: insights into dose, time, and mechanisms. Arterioscler. Thromb. Vasc. Biol. 41, 628–637 (2021).
Google Scholar
McAlpine, C. S. et al. Sleep modulates haematopoiesis and protects against atherosclerosis. Nature 566, 383–387 (2019).
Google Scholar
Cappuccio, F. P., Cooper, D., D’Elia, L., Strazzullo, P. & Miller, M. A. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Eur. Heart J. 32, 1484–1492 (2011).
Google Scholar
Engert, L. C., Mullington, J. M. & Haack, M. Prolonged experimental sleep disturbance affects the inflammatory resolution pathways in healthy humans. Brain Behav. Immun. 113, 12–20 (2023).
Google Scholar
Brezinski, D. A., Nesto, R. W. & Serhan, C. N. Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy. Circulation 86, 56–63 (1992).
Google Scholar
Shen, J. et al. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J. Clin. Invest. 98, 2201–2208 (1996).
Google Scholar
Serhan, C. N. et al. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J. Immunol. 171, 6856–6865 (2003).
Google Scholar
Merched, A. J., Ko, K., Gotlinger, K. H., Serhan, C. N. & Chan, L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J. 22, 3595–3606 (2008).
Google Scholar
Merched, A. J., Serhan, C. N. & Chan, L. Nutrigenetic disruption of inflammation-resolution homeostasis and atherogenesis. J. Nutrigenet Nutrigenomics 4, 12–24 (2011).
Google Scholar
Dwyer, J. H. et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N. Engl. J. Med. 350, 29–37 (2004).
Google Scholar
Fredman, G. et al. An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. Nat. Commun. 7, 12859 (2016).
Google Scholar
Thul, S., Labat, C., Temmar, M., Benetos, A. & Back, M. Low salivary resolvin D1 to leukotriene B4 ratio predicts carotid intima media thickness: a novel biomarker of non-resolving vascular inflammation. Eur. J. Prev. Cardiol. 24, 903–906 (2017).
Google Scholar
Bazan, H. A. et al. Circulating inflammation-resolving lipid mediators RvD1 and DHA are decreased in patients with acutely symptomatic carotid disease. Prostaglandins Leukot. Essent. Fat. Acids 125, 43–47 (2017).
Google Scholar
Sun, C. et al. Acute coronary syndrome may be associated with decreased resolvin D1-to-leukotriene B4 ratio. Int. Heart J. 64, 22–27 (2023).
Google Scholar
Viola, J. R. et al. Resolving lipid mediators maresin 1 and resolvin D2 prevent atheroprogression in mice. Circ. Res. 119, 1030–1038 (2016).
Google Scholar
Decker, C., Sadhu, S. & Fredman, G. Pro-resolving ligands orchestrate phagocytosis. Front. Immunol. 12, 660865 (2021).
Google Scholar
Thorp, E., Cui, D., Schrijvers, D. M., Kuriakose, G. & Tabas, I. Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe−/− mice. Arterioscler. Thromb. Vasc. Biol. 28, 1421–1428 (2008).
Google Scholar
Schrijvers, D. M., De Meyer, G. R., Herman, A. G. & Martinet, W. Phagocytosis in atherosclerosis: molecular mechanisms and implications for plaque progression and stability. Cardiovasc. Res. 73, 470–480 (2007).
Google Scholar
Ait-Oufella, H. et al. Defective mer receptor tyrosine kinase signaling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28, 1429–1431 (2008).
Google Scholar
Kojima, Y. et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536, 86–90 (2016).
Google Scholar
Tabas, I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10, 36–46 (2010).
Google Scholar
Doran, A. C., Yurdagul, A. Jr. & Tabas, I. Efferocytosis in health and disease. Nat. Rev. Immunol. 20, 254–267 (2020).
Google Scholar
Cai, B. et al. MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation. Proc. Natl Acad. Sci. USA 113, 6526–6531 (2016).
Google Scholar
Cai, B. et al. MerTK signaling in macrophages promotes the synthesis of inflammation resolution mediators by suppressing CaMKII activity. Sci. Signal. 11, eaar3721 (2018).
Google Scholar
Cai, B. et al. MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis. J. Clin. Invest. 127, 564–568 (2017).
Google Scholar
Yurdagul, A. Jr. et al. Macrophage metabolism of apoptotic cell-derived arginine promotes continual efferocytosis and resolution of injury. Cell Metab. 31, 518–533.e10 (2020).
Google Scholar
Ampomah, P. B. et al. Macrophages use apoptotic cell-derived methionine and DNMT3A during efferocytosis to promote tissue resolution. Nat. Metab. 4, 444–457 (2022).
Google Scholar
Gerlach, B. D. et al. Resolvin D1 promotes the targeting and clearance of necroptotic cells. Cell Death Differ. 41, 1062–1075 (2019).
Jarr, K. U. et al. Effect of CD47 blockade on vascular inflammation. N. Engl. J. Med. 384, 382–383 (2021).
Google Scholar
Tsuda, S. et al. Novel mechanism of regulation of the 5-lipoxygenase/leukotriene B4 pathway by high-density lipoprotein in macrophages. Sci. Rep. 7, 12989 (2017).
Google Scholar
Rymut, N. et al. Resolvin D1 promotes efferocytosis in aging by limiting senescent cell-induced MerTK cleavage. FASEB J. 34, 597–609 (2019).
Google Scholar
Baker, D. J. et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479, 232–236 (2011).
Google Scholar
Childs, B. G. et al. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science 354, 472–477 (2016).
Google Scholar
Rayner, K. J. Cell death in the vessel wall: the good, the bad, the ugly. Arterioscler. Thromb. Vasc. Biol. 37, e75–e81 (2017).
Google Scholar
Hosseini, Z. et al. Resolvin D1 enhances necroptotic cell clearance through promoting macrophage fatty acid oxidation and oxidative phosphorylation. Arterioscler. Thromb. Vasc. Biol. 41, 1062–1075 (2021).
Google Scholar
Sharma, M. et al. Regulatory T cells license macrophage pro-resolving functions during atherosclerosis regression. Circ. Res. 127, 335–353 (2020).
Google Scholar
Salic, K. et al. Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin. Atherosclerosis 250, 158–165 (2016).
Google Scholar
Petri, M. H. et al. Aspirin-triggered lipoxin inhibits atherosclerosis progression in apolipoprotein E−/− mice. Br. J. Pharmacol. 174, 4043–4054 (2017).
Google Scholar
Bardin, M. et al. The resolvin D2–GPR18 axis is expressed in human coronary atherosclerosis and transduces atheroprotection in apolipoprotein E deficient mice. Biochem. Pharmacol. 201, 115075 (2022).
Google Scholar
Hasturk, H. et al. Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. Arterioscler. Thromb. Vasc. Biol. 35, 1123–1133 (2015).
Google Scholar
Sadhu, S. et al. Radiation-induced macrophage senescence impairs resolution programs and drives cardiovascular inflammation. J. Immunol. 207, 1812–1823 (2021).
Google Scholar
Fuchs, A. et al. Subclinical coronary atherosclerosis and risk for myocardial infarction in a Danish cohort: a prospective observational cohort study. Ann. Intern. Med. 176, 433–442 (2023).
Google Scholar
Hasturk, H. et al. Safety and preliminary efficacy of a novel host-modulatory therapy for reducing gingival inflammation. Front. Immunol. 12, 704163 (2021).
Google Scholar
Rahman, K. et al. Inflammatory Ly6Chi monocytes and their conversion to M2 macrophages drive atherosclerosis regression. J. Clin. Invest. 127, 2904–2915 (2017).
Google Scholar
Williams, K. J., Feig, J. E. & Fisher, E. A. Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nat. Clin. Pract. Cardiovasc. Med. 5, 91–102 (2008).
Google Scholar
Kwan, A. C., Aronis, K. N., Sandfort, V., Blumenthal, R. S. & Bluemke, D. A. Bridging the gap for lipid lowering therapy: plaque regression, coronary computed tomographic angiography, and imaging-guided personalized medicine. Expert. Rev. Cardiovasc. Ther. 15, 547–558 (2017).
Google Scholar
Welty, F. K. et al. Regression of human coronary artery plaque is associated with a high ratio of (18-hydroxy-eicosapentaenoic acid + resolvin E1) to leukotriene B4. FASEB J. 35, e21448 (2021).
Google Scholar
Zheng, J. J., Pena Calderin, E., Hill, B. G., Bhatnagar, A. & Hellmann, J. Exercise promotes resolution of acute inflammation by catecholamine-mediated stimulation of resolvin D1 biosynthesis. J. Immunol. 203, 3013–3022 (2019).
Google Scholar
Lamon-Fava, S. et al. Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation. Prostaglandins Leukot. Essent. Fat. Acids 164, 102219 (2021).
Google Scholar
Bhatt, D. L. et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N. Engl. J. Med. 380, 11–22 (2019).
Google Scholar
Budoff, M. J. et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur. Heart J. 41, 3925–3932 (2020).
Google Scholar
Huston, J. et al. A critical review of icosapent ethyl in cardiovascular risk reduction. Am. J. Cardiovasc. Drugs 23, 393–406 (2023).
Google Scholar
Nicholls, S. J. et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA 324, 2268–2280 (2020).
Google Scholar
Gerster, H. Can adults adequately convert alpha-linolenic acid (18:3n-3) to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3)? Int. J. Vitam. Nutr. Res. 68, 159–173 (1998).
Google Scholar
Rathod, K. S. et al. Accelerated resolution of inflammation underlies sex differences in inflammatory responses in humans. J. Clin. Invest. 127, 169–182 (2017).
Google Scholar
Filiberto, A. C. et al. Sex differences in specialized pro-resolving lipid mediators and their receptors in abdominal aortic aneurysms. JVS Vasc. Sci. 4, 100107 (2023).
Google Scholar
Filiberto, A. C. et al. Resolution of inflammation via RvD1/FPR2 signaling mitigates Nox2 activation and ferroptosis of macrophages in experimental abdominal aortic aneurysms. FASEB J. 36, e22579 (2022).
Google Scholar
Spinosa, M. et al. Resolvin D1 decreases abdominal aortic aneurysm formation by inhibiting NETosis in a mouse model. J. Vasc. Surg. 68, 93S–103S (2018).
Google Scholar
Pope, N. H. et al. D-series resolvins inhibit murine abdominal aortic aneurysm formation and increase M2 macrophage polarization. FASEB J. 30, 4192–4201 (2016).
Google Scholar
Wu, B., Mottola, G., Schaller, M., Upchurch, G. R. Jr. & Conte, M. S. Resolution of vascular injury: specialized lipid mediators and their evolving therapeutic implications. Mol. Asp. Med. 58, 72–82 (2017).
Google Scholar
Krishnamoorthy, S. et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc. Natl Acad. Sci. USA 107, 1660–1665 (2010).
Google Scholar
Folco, E. J. et al. Neutrophil extracellular traps induce endothelial cell activation and tissue factor production through interleukin-1α and cathepsin G. Arterioscler. Thromb. Vasc. Biol. 38, 1901–1912 (2018).
Google Scholar
Yalcinkaya, M. et al. Cholesterol accumulation in macrophages drives NETosis in atherosclerotic plaques via IL-1β secretion. Cardiovasc. Res. 119, 969–981 (2023).
Google Scholar
Dona, M. et al. Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood 112, 848–855 (2008).
Google Scholar
Szymanska, P., Luzak, B., Milowska, K. & Golanski, J. The anti-aggregative potential of resolvin E1 on human platelets. Molecules 28, 5323 (2023).
Google Scholar
Cherpokova, D. et al. Resolvin D4 attenuates the severity of pathological thrombosis in mice. Blood 134, 1458–1468 (2019).
Google Scholar
Hiram, R. Resolution-promoting autacoids demonstrate promising cardioprotective effects against heart diseases. Mol. Biol. Rep. 49, 5179–5197 (2022).
Google Scholar
Tourki, B., Black, L. M., Kain, V. & Halade, G. V. Lipoxygenase inhibitor ML351 dysregulated an innate inflammatory response leading to impaired cardiac repair in acute heart failure. Biomed. Pharmacother. 139, 111574 (2021).
Google Scholar
Halade, G. V. et al. Arachidonate 5-lipoxygenase is essential for biosynthesis of specialized pro-resolving mediators and cardiac repair in heart failure. Am. J. Physiol. Heart Circ. Physiol. 323, H721–H737 (2022).
Google Scholar
Halade, G. V., Kain, V. & Serhan, C. N. Immune responsive resolvin D1 programs myocardial infarction-induced cardiorenal syndrome in heart failure. FASEB J. 32, 3717–3729 (2018).
Google Scholar
Tourki, B. et al. Lack of resolution sensor drives age-related cardiometabolic and cardiorenal defects and impedes inflammation-resolution in heart failure. Mol. Metab. 31, 138–149 (2020).
Google Scholar
Chen, J. et al. Formyl peptide receptor type 2 (FPR2) deficiency in myeloid cells amplifies sepsis-induced cardiac dysfunction. J. Innate Immun. 15, 548–561 (2023).
Google Scholar
Lau, E. S. et al. Eicosanoid and eicosanoid-related inflammatory mediators and exercise intolerance in heart failure with preserved ejection fraction. Nat. Commun. 14, 7557 (2023).
Google Scholar
Qintar, M. et al. Noncardiac chest pain after acute myocardial infarction: frequency and association with health status outcomes. Am. Heart J. 186, 1–11 (2017).
Google Scholar
Gilbert, K., Bernier, J., Godbout, R. & Rousseau, G. Resolvin D1, a metabolite of omega-3 polyunsaturated fatty acid, decreases post-myocardial infarct depression. Mar. Drugs 12, 5396–5407 (2014).
Google Scholar
Xu, Z. Z. et al. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat. Med. 16, 592–597 (2010).
Google Scholar
Halade, G. V. et al. Race-based and sex-based differences in bioactive lipid mediators after myocardial infarction. Esc. Heart Fail. 7, 1700–1710 (2020).
Google Scholar
Mozaffarian, D. et al. Heart disease and stroke statistics – 2015 update: a report from the American Heart Association. Circulation 131, e29–e322 (2015).
Google Scholar
Bibbins-Domingo, K. et al. Racial differences in incident heart failure among young adults. N. Engl. J. Med. 360, 1179–1190 (2009).
Google Scholar
Serhan, C. N. et al. The atlas of inflammation resolution (AIR). Mol. Asp. Med. 74, 100894 (2020).
Google Scholar
Martin, R. M. et al. Breastfeeding and atherosclerosis: intima-media thickness and plaques at 65-year follow-up of the Boyd Orr cohort. Arterioscler. Thromb. Vasc. Biol. 25, 1482–1488 (2005).
Google Scholar
McGill, H. C. Jr. et al. Origin of atherosclerosis in childhood and adolescence. Am. J. Clin. Nutr. 72, 1307S–1315S (2000).
Google Scholar
Lopez-Melgar, B. et al. Short-term progression of multiterritorial subclinical atherosclerosis. J. Am. Coll. Cardiol. 75, 1617–1627 (2020).
Google Scholar
Arnardottir, H., Orr, S. K., Dalli, J. & Serhan, C. N. Human milk proresolving mediators stimulate resolution of acute inflammation. Mucosal Immunol. 9, 757–766 (2016).
Google Scholar
Weiss, G. A. et al. High levels of anti-inflammatory and pro-resolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels in human milk during the first month of lactation. Lipids Health Dis. 12, 89 (2013).
Google Scholar
Robinson, D. T. et al. Long chain fatty acids and related pro-inflammatory, specialized pro-resolving lipid mediators and their intermediates in preterm human milk during the first month of lactation. Prostaglandins Leukot. Essent. Fat. Acids 121, 1–6 (2017).
Google Scholar
Arnardottir, H. H., Dalli, J., Colas, R. A., Shinohara, M. & Serhan, C. N. Aging delays resolution of acute inflammation in mice: reprogramming the host response with novel nano-proresolving medicines. J. Immunol. 193, 4235–4244 (2014).
Google Scholar
Doyle, R., Sadlier, D. M. & Godson, C. Pro-resolving lipid mediators: agents of anti-ageing? Semin. Immunol. 40, 36–48 (2018).
Google Scholar
Fitzgerald, H. et al. Resolvin D2-GPR18 enhances bone marrow function and limits steatosis and hepatic collagen accumulation in aging. Am. J. Pathol. 193, 1953–1968 (2023).
Google Scholar
Libreros, S., Nshimiyimana, R., Lee, B. & Serhan, C. N. Infectious neutrophil deployment is regulated by resolvin D4. Blood 142, 589–606 (2023).
Google Scholar
Pirault, J. & Back, M. Lipoxin and resolvin receptors transducing the resolution of inflammation in cardiovascular disease. Front. Pharmacol. 9, 1273 (2018).
Google Scholar
Spite, M. & Fredman, G. Insights into the role of the resolvin D2-GPR18 signaling axis in cardiovascular physiology and disease. Adv. Pharmacol. 97, 257–281 (2023).
Google Scholar
Petri, M. H. et al. The role of the FPR2/ALX receptor in atherosclerosis development and plaque stability. Cardiovasc. Res. 105, 65–74 (2015).
Google Scholar
Drechsler, M. et al. Annexin A1 counteracts chemokine-induced arterial myeloid cell recruitment. Circ. Res. 116, 827–835 (2015).
Google Scholar
Fredman, G. et al. Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci. Transl. Med. 7, 275ra220 (2015).
Google Scholar
Arnardottir, H. et al. The resolvin D1 receptor GPR32 transduces inflammation resolution and atheroprotection. J. Clin. Invest. 131, e14288 (2021).
Google Scholar
Laguna-Fernandez, A. et al. ERV1/ChemR23 signaling protects against atherosclerosis by modifying oxidized low-density lipoprotein uptake and phagocytosis in macrophages. Circulation 138, 1693–1705 (2018).
Google Scholar
van der Vorst, E. P. C. et al. Hematopoietic chemR23 (chemerin receptor 23) fuels atherosclerosis by sustaining an M1 macrophage-phenotype and guidance of plasmacytoid dendritic cells to murine lesions – brief report. Arterioscler. Thromb. Vasc. Biol. 39, 685–693 (2019).
Google Scholar
Lipscomb, M. et al. Resolvin D2-GPR18 signaling on myeloid cells limits plaque necrosis. Preprint at bioRxiv (2023).
Moore, F. D. Metabolic Care of the Surgical Patient Section III (Saunders, 1959).
Uzun, G. et al. Can lipid mediators and free fatty acids guide acute coronary syndrome diagnosis and treatment? Lab. Med. 2, lmad042 (2023).
Capó, X. et al. Resolvins as proresolving inflammatory mediators in cardiovascular disease. Eur. J. Med. Chem. 153, 123–130 (2018).
Google Scholar
Hamilton, J. A., Hasturk, H., Kantarci, A., Serhan, C. N. & Van Dyke, T. Atherosclerosis, periodontal disease, and treatment with resolvins. Curr. Atheroscler. Rep. 19, 57 (2017).
Google Scholar
Eswarappa, M., Neylan, T. C., Whooley, M. A., Metzler, T. J. & Cohen, B. E. Inflammation as a predictor of disease course in posttraumatic stress disorder and depression: a prospective analysis from the Mind Your Heart Study. Brain. Behav. Immun. 75, 220–227 (2019).
Google Scholar
Halade, G. V., Norris, P. C., Kain, V., Serhan, C. N. & Ingle, K. A. Splenic leukocytes define the resolution of inflammation in heart failure. Sci. Signal. 11, eaao1818 (2018).
Google Scholar
Park, J., Langmead, C. J. & Riddy, D. M. New advances in targeting the resolution of inflammation: implications for specialized pro-resolving mediator GPCR drug discovery. ACS Pharmacol. Transl. Sci. 3, 88–106 (2020).
Google Scholar
Norris, P. C. & Serhan, C. N. Metabololipidomic profiling of functional immunoresolvent clusters and eicosanoids in mammalian tissues. Biochem. Biophys. Res. Commun. 504, 553–561 (2018).
Google Scholar
Fu, X. et al. High sensitivity and wide linearity LC-MS/MS method for oxylipin quantification in multiple biological samples. J. Lipid Res. 63, 100302 (2022).
Google Scholar
Hersberger, M. Potential role of the lipoxygenase derived lipid mediators in atherosclerosis: leukotrienes, lipoxins and resolvins. Clin. Chem. Lab. Med. 48, 1063–1073 (2010).
Google Scholar
Mas, E., Croft, K. D., Zahra, P., Barden, A. & Mori, T. A. Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin. Chem. 58, 1476–1484 (2012).
Google Scholar
Norris, P. C. et al. Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation. Sci. Rep. 8, 18050 (2018).
Google Scholar
Biagini, D. et al. Salivary lipid mediators: key indexes of inflammation regulation in heart failure disease. Free. Radic. Biol. Med. 201, 55–65 (2023).
Google Scholar
Keeley, E. C. et al. Specialized proresolving mediators in symptomatic women with coronary microvascular dysfunction (from the Women’s Ischemia Trial to Reduce Events in Nonobstructive CAD [WARRIOR] Trial). Am. J. Cardiol. 162, 1–5 (2022).
Google Scholar
Ramirez, J. L. et al. Fish oil increases specialized pro-resolving lipid mediators in PAD (The OMEGA-PAD II Trial). J. Surg. Res. 238, 164–174 (2019).
Google Scholar
Taylor, H. A. et al. Scientific opportunities in resilience research for cardiovascular health and wellness. Report from a National Heart, Lung, and Blood Institute workshop. FASEB J. 36, e22639 (2022).
Google Scholar
Calder, P. C. Eicosapentaenoic and docosahexaenoic acid derived specialised pro-resolving mediators: concentrations in humans and the effects of age, sex, disease and increased omega-3 fatty acid intake. Biochimie 178, 105–123 (2020).
Google Scholar
Soehnlein, O. & Libby, P. Targeting inflammation in atherosclerosis–from experimental insights to the clinic. Nat. Rev. Drug. Discov. 20, 589–610 (2021).
Google Scholar
Fredman, G. & Tabas, I. Boosting inflammation resolution in atherosclerosis: the next frontier for therapy. Am. J. Pathol. 187, 1211–1221 (2017).
Google Scholar
Serhan, C. N. Resolution phases of inflammation: novel endogenous anti-inflammatory and pro-resolving lipid mediators and pathways. Annu. Rev. Immunol. 25, 101–137 (2007).
Google Scholar
Brennan, E. et al. Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function. Nat. Rev. Nephrol. 17, 725–739 (2021).
Google Scholar
Thatcher, T. H., Freeberg, M. A. T., Myo, Y. P. A. & Sime, P. J. Is there a role for specialized pro-resolving mediators in pulmonary fibrosis? Pharmacol. Ther. 247, 108460 (2023).
Google Scholar
Spite, M. et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461, 1287–1291 (2009).
Google Scholar
Leroy, V. et al. Resolution of post-lung transplant ischemia-reperfusion injury is modulated via Resolvin D1-FPR2 and Maresin 1-LGR6 signaling. J. Heart Lung Transpl. 42, 562–574 (2023).
Google Scholar
Shimizu, T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 49, 123–150 (2009).
Google Scholar
Woodward, D. F., Jones, R. L. & Narumiya, S. International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol. Rev. 63, 471–538 (2011).
Google Scholar
Serhan, C. N. et al. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 34, 14609–14615 (1995).
Google Scholar
Sun, Y. P. et al. Anti-inflammatory and pro-resolving properties of benzo-lipoxin A4 analogs. Prostaglandins Leukot. Essent. Fat. Acids 81, 357–366 (2009).
Google Scholar
Orr, S. K., Colas, R. A., Dalli, J., Chiang, N. & Serhan, C. N. Proresolving actions of a new resolvin D1 analog mimetic qualifies as an immunoresolvent. Am. J. Physiol. Lung Cell Mol. Physiol. 308, L904–L911 (2015).
Google Scholar
Sun, Y. P. et al. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J. Biol. Chem. 282, 9323–9334 (2007).
Google Scholar
Chiang, N. et al. Identification of chemotype agonists for human resolvin D1 receptor DRV1 with pro-resolving functions. Cell Chem. Biol. 26, 244–254.e4 (2019).
Google Scholar
US National Library of Medicine. ClinicalTrials.gov (2010).
OphthalmologyWeb. Resolvyx Pharmaceuticals, Inc. announces positive data from phase 2 clinical trial of the Resolvin RX-10045 in patients with dry eye syndrome. OphthalmologyWeb (2009).
Sulciner, M. L. et al. Resolvins suppress tumor growth and enhance cancer therapy. J. Exp. Med. 215, 115–140 (2018).
Google Scholar
Lance, K. D. et al. Unidirectional and sustained delivery of the proresolving lipid mediator resolvin D1 from a biodegradable thin film device. J. Biomed. Mater. Res. A 105, 31–41 (2017).
Google Scholar
Serhan, C. N., Lundberg, U., Weissmann, G. & Samuelsson, B. Formation of leukotrienes and hydroxy acids by human neutrophils and platelets exposed to monosodium urate. Prostaglandins 27, 563–581 (1984).
Google Scholar
Vane, J. R. Biomedicine. Back to an aspirin a day? Science 296, 474–475 (2002).
Google Scholar
Fishbein, A., Hammock, B. D., Serhan, C. N. & Panigrahy, D. Carcinogenesis: failure of resolution of inflammation? Pharmacol. Ther. 218, 107670 (2021).
Google Scholar
Fredman, G., Van Dyke, T. E. & Serhan, C. N. Resolvin E1 regulates adenosine diphosphate activation of human platelets. Arterioscler. Thromb. Vasc. Biol. 30, 2005–2013 (2010).
Google Scholar
Uno, H. et al. Immunonutrition suppresses acute inflammatory responses through modulation of resolvin E1 in patients undergoing major hepatobiliary resection. Surgery 160, 228–236 (2016).
Google Scholar
Hartling, I. et al. Quantitative profiling of inflammatory and pro-resolving lipid mediators in human adolescents and mouse plasma using UHPLC-MS/MS. Clin. Chem. Lab. Med. 59, 1811–1823 (2021).
Google Scholar
Brennan, E. P. et al. Lipoxins protect against inflammation in diabetes-associated atherosclerosis. Diabetes 67, 2657–2667 (2018).
Google Scholar
Kamaly, N. et al. Targeted interleukin-10 nanotherapeutics developed with a microfluidic chip enhance resolution of inflammation in advanced atherosclerosis. ACS Nano 10, 5280–5292 (2016).
Google Scholar
Kusters, D. H. et al. Pharmacological treatment with annexin A1 reduces atherosclerotic plaque burden in LDLR−/− mice on Western Type Diet. PLoS ONE 10, e0130484 (2015).
Google Scholar
Chiang, N. & Serhan, C. N. Specialized pro-resolving mediator network: an update on production and actions. Essays Biochem. 64, 443–462 (2020).
Google Scholar
Chiang, N. et al. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484, 524–528 (2012).
Google Scholar
Elajami, T. K. et al. Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J. 30, 2792–2801 (2016).
Google Scholar
Hiram, R. et al. An inflammation resolution-promoting intervention prevents atrial fibrillation due to left-ventricular dysfunction. Cardiovasc. Res. (2023).
link